TG Therapeutics | TGTX - Operating Profit


TG Therapeutics reported $29.36M in Operating Profit for its fiscal quarter ending in September of 2025.





Operating Profit Change Date
AbbVie USD 5.81B 1.23B Dec/2025
Alaunos Therapeutics USD -1.19M 432K Sep/2025
Amgen USD 3.96B 464M Dec/2025
Ardelyx USD 4.67M 19.07M Sep/2025
Arrowhead Research USD 40.81M 3.3M Dec/2025
Bayer EUR -543M 556M Sep/2025
Biogen USD 659.6M 192.2M Sep/2025
Corcept Therapeutics USD 10.22M 16.46M Sep/2025
Dynavax Technologies USD 21.27M 10.41M Sep/2025
Gilead Sciences USD 3.51B 810M Sep/2025
J&J USD 5.59B 1.81B Dec/2025
Novartis USD 4.5B 363M Sep/2025
PTC Therapeutics USD 3.49M 38.35M Sep/2025
Regeneron Pharmaceuticals USD 898.6M 211.3M Dec/2025
Roche Holding CHF 9.56B 3.8B Dec/2025
TG Therapeutics USD 29.36M 5.48M Sep/2025
Vertex Pharmaceuticals USD 1.24B 84.6M Sep/2025